Sandra Castaño-Díez

13PUBLICATIONS
58CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMedical virologyCancer therapy (excl. chemotherapy and radiation therapy)Medical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 30, 2026
ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

|Jan 30, 2026
Unveiling relative lymphopenia and elevated monocyte-to-lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)-Proposal of the objective prognostic index for CMML (OPIC).

Xavier Calvo, Abora Rial-Villavecchia, David Roman-Bravo

|May 14, 2025
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Carlos Jimenez-Vicente, Aina Cardus, Sandra Castaño-Diez

|Jan 08, 2025
At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.

Alexandra Martínez-Roca, Carlos Jiménez-Vicente, Beatriz Merchán

|Oct 10, 2024
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Sandra Castaño-Díez, Mònica López-Guerra, Inés Zugasti

|Sep 30, 2024
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

Sandra Castaño-Díez, José Ramón Álamo, Mònica López-Guerra

Pageof 3

Frequent Collaborators

8 joint publications

Francesca Guijarro

5 joint publications

Jordi Esteve

5 joint publications

Carlos Jiménez-Vicente

4 joint publications

José Ramón Álamo Moreno